Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

References

• Chiricozzi A, Veraldi S, Fabbrocini G, et al. The Hidradenitis Suppurativa (HS) “Multidisciplinary Unit”: a rationale and practical proposal for an organised clinical approach. Eur J Dermatol. 2018;28(2):274–275. doi:10.1684/ejd.2018.3254
   PubMed Web of Science ®Google Scholar
• Martora F, Martora L, Fabbrocini G, Marasca C. A case of pemphigus vulgaris and hidradenitis suppurativa: may systemic steroids be considered in the standard management of hidradenitis suppurativa? SkinAppendageDisord. 2022;8(3):265–268.
   Google Scholar
• Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045–1058.
   PubMed Web of Science ®Google Scholar
• Stephan C, Kurban M, Abbas O. Reply to: “Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis”. J Am Acad Dermatol. 2020;83(5):e371.
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur AcadDermatolVenereol. 2021;35(1):50–61.
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Battista T, Fabbrocini G, Ruggiero A. Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: ‘Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa’. Clin Experimental Dermatol. 2022;47(11):2026–2028.
   PubMed Web of Science ®Google Scholar
• Maronese CA, Moltrasio C, Genovese G, Marzano AV. Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol. 2023;1–21. doi:10.1080/1744666X.2023.2298356
   PubMedGoogle Scholar
• Maronese CA, Ingram JR, Marzano AV. Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa? Br J Dermatol. 2023;189(4):467–468. doi:10.1093/bjd/ljad224
   PubMedGoogle Scholar
• Kimball AB, Okun MM, Williams DA, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016;375(5):422–434. doi:10.1056/NEJMoa1504370
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Okun MM, Forman SB, et al. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the Phase III randomized placebo-controlled PIONEER trials. Br J Dermatol. 2019;181(5):967–975. doi:10.1111/bjd.17919
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Okun MM, Prens EP, et al. Long-term Adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60–69.e2. doi:10.1016/j.jaad.2018.05.040
   PubMed Web of Science ®Google Scholar
• Martora F, Megna M, Battista T, et al. Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: a review of the real-life experience. ClinCosmetInvestigDermatol. 2023;16:135–148.
   Google Scholar
• Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747–761. doi:10.1016/S0140-6736(23)00022-3
   PubMed Web of Science ®Google Scholar
• Novartis Europharm Limited. Cosentyx® (secukinumab): summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf. Accessed May, 2023.
   Google Scholar
• Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401–1409. doi:10.1111/bjd.15748
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur AcadDermatolVenereol. 2015;29(4):619–644. doi:10.1111/jdv.12966
   PubMed Web of Science ®Google Scholar
• Fernandez-Crehuet P, Haselgruber S, Padial-Gomez A, et al. Short-term effectiveness, safety, and potential predictors of response of secukinumab in patients with severe hidradenitis suppurativa refractory to biologic therapy: a multicenter observational retrospective study. Dermatol Ther. 2023;13(4):1029–1038. doi:10.1007/s13555-023-00906-2
   PubMed Web of Science ®Google Scholar
• Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609–611. doi:10.1111/bjd.17822
   PubMed Web of Science ®Google Scholar
• Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol. 2020;82(6):1524–1526. doi:10.1016/j.jaad.2020.02.005
   PubMed Web of Science ®Google Scholar
• Reguiaï Z, Fougerousse AC, Maccari F, Bécherel PA. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur AcadDermatolVenereol. 2020;34(11):e750–e751.
   PubMed Web of Science ®Google Scholar
• Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting. AcadDermatolVenereol. 2021;35(7):e441–e442.
   Google Scholar
• Melgosa Ramos FJ, García Ruiz R, Estébanez Corrales A, MateuPuchades A. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: a retrospective single-centre case series (23 patients). J Eur Acad Dermatol Venereol. 2022;37(4):e517–e519.
   PubMed Web of Science ®Google Scholar
• Marasca C, Megna M, Balato A, Balato N, Napolitano M, Fabbrocini G. Secukinumab and hidradenitis suppurativa: friends or foes? JAAD Case Rep. 2019;5(2):184–187. doi:10.1016/j.jdcr.2018.12.002
   PubMedGoogle Scholar
• Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2018;179(1):182–185. doi:10.1111/bjd.15769
   PubMed Web of Science ®Google Scholar
• Schuch A, Fischer T, Boehner A, Biedermann T, Volz T. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab. Acta Derm Venereol. 2018;98(1):151–152. doi:10.2340/00015555-2794
   PubMed Web of Science ®Google Scholar
• Jørgensen AR, Yao Y, Thomsen SF. Therapeutic response to secukinumab in a 36-year-old woman with hidradenitis suppurativa. Case Rep Dermatol Med. 2018;2018:8685136. doi:10.1155/2018/8685136
   PubMedGoogle Scholar
• Matusiak Ł, Szczęch J, Bieniek A, Nowicka-Suszko D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76(4):670–675. doi:10.1016/j.jaad.2016.10.042
   PubMed Web of Science ®Google Scholar
• Saraçöztürk G, Ergun T, PekerEyüboğlu İ, Akkiprik M. Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa. Cytokine. 2021;144:155585. doi:10.1016/j.cyto.2021.155585
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Picone V, Fornaro L, Megna M, Fabbrocini G. How adalimumab impacts antibiotic prescriptions in patients affected by hidradenitis suppurativa: a 1-year prospective study and retrospective analysis. J Clin Med. 2023;12(3):837. doi:10.3390/jcm12030837
   PubMed Web of Science ®Google Scholar
• Hunger RE, Laffitte E, Läuchli S, et al. Swiss practice recommendations for the management of hidradenitis suppurativa/acne inversa. Dermatology. 2017;233(2–3):113–119. doi:10.1159/000477459
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Martora F, Picone V, Marano L, Fabbrocini G, Marasca C. Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review. Biomedicines. 2022;10(2):455. doi:10.3390/biomedicines10020455
   PubMed Web of Science ®Google Scholar
• Salvador-Rodriguez L, Montero-Vílchez T, Arias-Santiago S, Molina-Leyva A. Paradoxical hidradenitis suppurativa in patients receiving TNF-α inhibitors: case series, systematic review, and case meta-analysis. Dermatology. 2020;236(4):307–313. doi:10.1159/000506074
   PubMed Web of Science ®Google Scholar
• Delobeau M, Abdou A, Puzenat E, et al. Observational case series on Adalimumab-induced paradoxical hidradenitis suppurativa. J Dermatol Treat. 2016;27(3):251–253. doi:10.3109/09546634.2015.1094179
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Marasca C, Battista T, Megna M. Paradoxical hidradenitis suppurativa induced by Adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on ‘Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab’. Clin Experimental Dermatol. 2023;48(6):701–703. doi:10.1093/ced/llad082
   PubMed Web of Science ®Google Scholar
• Martora F, Marasca C, Fabbrocini G, Ruggiero A. Strategies adopted in a southern Italian referral centre to reduce Adalimumab discontinuation: comment on “Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?”. Clin Experimental Dermatol. 2022;47(10):1864–1865. doi:10.1111/ced.15291
   PubMed Web of Science ®Google Scholar
• Dudink K, Bouwman K, Chen Y, et al. Guselkumab for hidradenitis suppurativa: a Phase II, open-label, mode-of-action study. Br J Dermatol. 2023;188(5):601–609. doi:10.1093/bjd/ljad010
   PubMed Web of Science ®Google Scholar
• Melgosa Ramos FJ, García Ruiz R, MateuPuchades A, AlfagemeRoldán F. Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: a retrospective bicentric experience. Dermatologic Therapy. 2022;35(7):e15558. doi:10.1111/dth.15558
   PubMed Web of Science ®Google Scholar
• Kimball AB, Podda M, Alavi A, et al. Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: a Phase 2 randomized study. J Eur Acad Dermatol Venereol. 2023;37(10):2098–2108. doi:10.1111/jdv.19252
   PubMed Web of Science ®Google Scholar
• Martora F, Scalvenzi M, Battista T, et al. Guselkumab, risankizumab, and tildrakizumab in the management of hidradenitis suppurativa: a review of existing trials and real-life data. Clin Cosmet Invest Dermatol. 2023;16:2525–2536. doi:10.2147/CCID.S418748
   PubMed Web of Science ®Google Scholar
• Kimball AB, Prens EP, Passeron T, et al. Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial. Dermatol Ther. 2023;13(5):1099–1111. doi:10.1007/s13555-023-00913-3
   PubMed Web of Science ®Google Scholar
• Martora F, Scalvenzi M, Ruggiero A, Potestio L, Battista T, Megna M. Hidradenitis suppurativa and JAK inhibitors: a review of the published literature. Medicina. 2023;59(4):801. doi:10.3390/medicina59040801
   PubMedGoogle Scholar
• Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, et al. Target molecules for future hidradenitis suppurativa treatment. Exper Dermatol. 2021;30(Suppl 1):8–17. doi:10.1111/exd.14338
   PubMedGoogle Scholar
• Hwang J, Rick J, Hsiao J, Shi VY. A review of IL-36: an emerging therapeutic target for inflammatory dermatoses. J Dermatol Treat. 2022;33(6):2711–2722. doi:10.1080/09546634.2022.2067819
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023;22(1):43–58. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023;22(1):25–41. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatologic Therapy. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Invest Drugs. 2023;32(6):537–552. doi:10.1080/13543784.2023.2219387
   PubMed Web of Science ®Google Scholar
• Fukaura R, Akiyama M. Targeting IL-36 in Inflammatory Skin Diseases. BioDrugs. 2023;37(3):279–293. doi:10.1007/s40259-023-00587-5
   PubMed Web of Science ®Google Scholar
• Alavi A, Hamzavi I, Brown K, et al. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two Phase II studies. Br J Dermatol. 2022;186(5):803–813. doi:10.1111/bjd.20969
   PubMed Web of Science ®Google Scholar
• Martora F, Picone V, Fabbrocini G, Marasca C. Hidradenitis suppurativa flares following COVID-19 vaccination: a case series. JAAD Case Rep. 2022;23:42–45. doi:10.1016/j.jdcr.2022.03.008
   PubMedGoogle Scholar
• Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? J Med Virol. 2022;94(4):1292–1293. doi:10.1002/jmv.27535
   PubMed Web of Science ®Google Scholar
• Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. Dermatologic Therapy. 2022;35(2):e15225. doi:10.1111/dth.15225
   PubMed Web of Science ®Google Scholar
• Picone V, Martora F, Fabbrocini G, Marano L. ”Covid arm”: abnormal side effect after Moderna COVID-19 vaccine. Dermatologic Therapy. 2022;35(1):e15197. doi:10.1111/dth.15197
   PubMed Web of Science ®Google Scholar
• Jenkins T, Isaac J, Edwards A, Okoye GA. Hidradenitis Suppurativa. Dermatol Clin. 2023;41(3):471–479. doi:10.1016/j.det.2023.02.001
   PubMed Web of Science ®Google Scholar
• Bukvić Mokos Z, Marinović B. Hidradenitis suppurativa: I. Clin Dermatol. 2023;41(5):549–550. doi:10.1016/j.clindermatol.2023.08.017
   PubMed Web of Science ®Google Scholar
• van Straalen KR, Prens EP, Gudjonsson JE. Insights into hidradenitis suppurativa. J Allergy Clin Immunol. 2022;149(4):1150–1161. doi:10.1016/j.jaci.2022.02.003
   PubMed Web of Science ®Google Scholar
• Choi E, Ooi XT, Chandran NS. Hidradenitis suppurativa in pediatric patients. J Am Acad Dermatol. 2022;86(1):140–147. doi:10.1016/j.jaad.2020.08.045
   PubMed Web of Science ®Google Scholar
• Hasan SB, Harris C, Collier F. Hidradenitis suppurativa. BMJ. 2022;379:e068383. doi:10.1136/bmj-2021-068383
   PubMedGoogle Scholar